Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma is a research paper published in Journal of Hepatology (2021). On theSindex it has a DataRank of 1.1. It has been cited 24 times, with 24 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.483
From this paper's citation signal
Citation Network Contribution
0.647
From 18 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 24 citers.
AbbVie
Grant: NCT 00858871
AbbVie
Grant: NCT 0200995930
Cancer Research UK
Grant: C42738/A24868
National Institutes of Health
Grant: 5P30CA045508-31
Cancer Research UK
Grant: 26813
NCI NIH HHS
Grant: P30 CA045508
Medical Research Council
Grant: MR/M013227/1
Engineering and Physical Sciences Research Council
Grant: EP/N014499/1
Cancer Research UK
Grant: 24868
Cancer Research UK
Grant: 29681
Cancer Research UK
Grant: 19924
Pershing Square Foundation
Mark Foundation For Cancer Research
Cold Spring Harbor Laboratory
MeSH Terms
Keywords